227 related articles for article (PubMed ID: 31446059)
21. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers.
Oikawa T; Kamiya A; Zeniya M; Chikada H; Hyuck AD; Yamazaki Y; Wauthier E; Tajiri H; Miller LD; Wang XW; Reid LM; Nakauchi H
Hepatology; 2013 Apr; 57(4):1469-83. PubMed ID: 23175232
[TBL] [Abstract][Full Text] [Related]
22. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
23. Long noncoding HOXA11-AS knockdown suppresses the progression of non-small cell lung cancer by regulating miR-3619-5p/SALL4 axis.
Xia H; Niu Q; Ding Y; Zhang Z; Yuan J; Jin W
J Mol Histol; 2021 Aug; 52(4):729-740. PubMed ID: 34050851
[TBL] [Abstract][Full Text] [Related]
24. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride.
Chen YY; Li ZZ; Ye YY; Xu F; Niu RJ; Zhang HC; Zhang YJ; Liu YB; Han BS
BMC Mol Biol; 2016 Mar; 17():6. PubMed ID: 26935744
[TBL] [Abstract][Full Text] [Related]
26. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma.
Yong KJ; Gao C; Lim JS; Yan B; Yang H; Dimitrov T; Kawasaki A; Ong CW; Wong KF; Lee S; Ravikumar S; Srivastava S; Tian X; Poon RT; Fan ST; Luk JM; Dan YY; Salto-Tellez M; Chai L; Tenen DG
N Engl J Med; 2013 Jun; 368(24):2266-76. PubMed ID: 23758232
[TBL] [Abstract][Full Text] [Related]
27. Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression.
Shen J; Chen M; Lee D; Law CT; Wei L; Tsang FH; Chin DW; Cheng CL; Lee JM; Ng IO; Wong CC; Wong CM
Gut; 2020 Feb; 69(2):329-342. PubMed ID: 31439637
[TBL] [Abstract][Full Text] [Related]
28. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex.
Gao C; Dimitrov T; Yong KJ; Tatetsu H; Jeong HW; Luo HR; Bradner JE; Tenen DG; Chai L
Blood; 2013 Feb; 121(8):1413-21. PubMed ID: 23287862
[TBL] [Abstract][Full Text] [Related]
29. The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma.
Zeng SS; Yamashita T; Kondo M; Nio K; Hayashi T; Hara Y; Nomura Y; Yoshida M; Hayashi T; Oishi N; Ikeda H; Honda M; Kaneko S
J Hepatol; 2014 Jan; 60(1):127-34. PubMed ID: 24012616
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
Caruso S; Calatayud AL; Pilet J; La Bella T; Rekik S; Imbeaud S; Letouzé E; Meunier L; Bayard Q; Rohr-Udilova N; Péneau C; Grasl-Kraupp B; de Koning L; Ouine B; Bioulac-Sage P; Couchy G; Calderaro J; Nault JC; Zucman-Rossi J; Rebouissou S
Gastroenterology; 2019 Sep; 157(3):760-776. PubMed ID: 31063779
[TBL] [Abstract][Full Text] [Related]
31. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
32. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
33. Super-Enhancer-Driven Long Non-Coding RNA LINC01503, Regulated by TP63, Is Over-Expressed and Oncogenic in Squamous Cell Carcinoma.
Xie JJ; Jiang YY; Jiang Y; Li CQ; Lim MC; An O; Mayakonda A; Ding LW; Long L; Sun C; Lin LH; Chen L; Wu JY; Wu ZY; Cao Q; Fang WK; Yang W; Soukiasian H; Meltzer SJ; Yang H; Fullwood M; Xu LY; Li EM; Lin DC; Koeffler HP
Gastroenterology; 2018 Jun; 154(8):2137-2151.e1. PubMed ID: 29454790
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
35. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
36. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression.
Tian Q; Xiao Y; Wu Y; Liu Y; Song Z; Gao W; Zhang J; Yang J; Zhang Y; Guo T; Dai F; Sun Z
Int J Mol Med; 2016 Nov; 38(5):1587-1595. PubMed ID: 28026002
[TBL] [Abstract][Full Text] [Related]
38. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids
Liu G; Kuang S; Cao R; Wang J; Peng Q; Sun C
FASEB J; 2019 Sep; 33(9):10089-10103. PubMed ID: 31199678
[TBL] [Abstract][Full Text] [Related]
39. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
[TBL] [Abstract][Full Text] [Related]
40. DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection.
Fan H; Cui Z; Zhang H; Mani SK; Diab A; Lefrancois L; Fares N; Merle P; Andrisani O
Oncogene; 2017 Apr; 36(17):2435-2445. PubMed ID: 27797380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
